ArticleLeukemia & lymphoma2015
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.
Article in Leukemia & lymphoma, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Technological features of blast identification in the cerebrospinal fluid: A systematic review of flow cytometry and laboratory haematology methods.International journal of laboratory hematology · 2022Pooled it
- Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.Annals of hematology · 2021Trial
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.The Lancet. Haematology · 2020Trial
- Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Trial
- Von Willebrand, factor VIII, and D-dimer levels as predictors of risk and clinical outcomes in acute myeloid leukemia.Clinical and experimental medicine · 2026Article
- Case Report: Optic nerve infiltration associated with sequential CRVO and CRAO in isolated CNS relapse of AML.Frontiers in medicine · 2026Article
- Unraveling Intractable Headache in Acute Myeloid Leukemia With Coexisting Migraines and Chiari Malformation.Cureus · 2025Article
- A Sudden Expansion: Acute Subdural Hematoma From Extramedullary Acute Myeloid Leukemia.Cureus · 2025Article
- Sugar-Coating or Zuckerguss Appearance on Magnetic Resonance Imaging in Leptomeningeal Carcinomatosis in a Patient with Acute Myeloid Leukemia.Annals of Indian Academy of Neurology · 2025Article
- Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/ hypomethylating agents.Haematologica · 2025Article
- The contemporary spectrum of radiotherapy for hematologic malignancies involving the central nervous system: From focal therapy to craniospinal.Seminars in radiation oncology · 2025Review
- Isolated central nervous system relapse in acute myeloid leukemia: a case report and review of therapeutic challenges.Frontiers in oncology · 2025Article
- Diagnosis and management of adult central nervous system leukemia.Blood science (Baltimore, Md.) · 2023Review
- Central Nervous System Prophylaxis and Treatment in Acute Leukemias.Current treatment options in oncology · 2022Review
- Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management.Current oncology reports · 2022Review
- CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials.Blood advances · 2021Article
- Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy.Oncology letters · 2021Article
- Emergent Radiotherapy for Leukemia-Induced Cranial Neuropathies Refractory to Intrathecal Therapy.Cureus · 2021Article
- A narrative review of central nervous system involvement in acute leukemias.Annals of translational medicine · 2021Review
- Metabolic Reprogramming and Cell Adhesion in Acute Leukemia Adaptation to the CNS Niche.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
It is thought that the low incidence of central nervous system (CNS) involvement in acute myeloid leukemia (AML) does not justify routine CNS prophylaxis, as high-dose cytarabine eliminates CNS disease. To investigate whether chemotherapy that does not include high-dose cytarabine increases the risk of CNS involvement, the medical records of 1412 newly diagnosed patients with AML were reviewed. In 1370 patients, lumbar puncture (LP) was performed only if clinically indicated, and CNS disease was detected in 45 (3.3%) patients. Another 42 patients underwent routine LP as part of an investigational protocol, and in eight (19%) CNS disease was detected (p < 0.0001). Risk factors included high lactate dehydrogenase, African-American ethnicity and young age. Patients receiving high-dose cytarabine and those who did not had similar rates of CNS involvement. Disease-free survival (DFS) and overall survival were shorter in patients with CNS involvement. It remains to be determined whether routine CNS prophylaxis would improve DFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.